Finland· FI-REL-REL65511

Bavencio

A avelumab product containing avelumab, registered in Finland by Abacus Medicine A/S. The same ATC class is registered in 12 of our 19 countries.

ATC L01FF04

Checked against Fimea (Finland) on

Informational only — not a medical device.

SOURCE REGISTER · FIFimea (Finland)normalisedBavencioATCL01FF04REGISTER NO.FI-REL-REL65511PACKS LISTED0CHECKEDSeptember 27, 2026

Where it is registered

Avelumab is registered in 12 of 19 countries.

Countries holding a registration under ATC L01FF04 (avelumab), each read from that country’s own register.

  • This record: Finland, from Fimea (Finland)
  • 8 of them publish a price we can compare per daily dose

Avelumab · ATC L01FF04

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Fimea (Finland)
Active substance
Avelumab
Manufacturer
Abacus Medicine A/S
Country
Finland (FI)
ATC code
L01FF04
ATC class
Avelumab
Defined daily dose
57.1 mg, P
Reimbursed
Not published by this register
Source register
Fimea (Finland)
Last checked
September 27, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

3 interactions on record for avelumab.

Graded by severity as the source publishes them — 3 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Avelumab · interactions on record

3 records

  • 3 severe

Most severe, free to view

  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • PomalidomideL04AX06severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Avelumab in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All avelumab products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Bavencio
  • Liechtenstein · Bavencio
  • Norway · Bavencio

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9363cf19-89f7-44c9-868a-fcc1817532c5
GET /v1/drugs/9363cf19-89f7-44c9-868a-fcc1817532c5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "ddd": "57.1",
  "form": "infuusiokonsentraatti, liuosta varten",
  "route": "Laskimoon",
  "ddd_unit": "mg",
  "strength": "20 mg/ml",
  "atc_label": "avelumabi",
  "ma_number": null,
  "auth_status": "Myyntilupa myönnetty",
  "eu_ma_number": "EU/1/17/1214/001",
  "fimea_rel_id": "REL65511",
  "authorised_at": "2026-08-03"
}

See everything about avelumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.